Medication Profile—Community Pharmacy
Patient Name: Mike Tell
Race: Caucasian
Address: 334 Unknown St.
Height: 5'11”
Age: 60
Weight: 266 lb
Gender: M
Allergies: NKA

Diagnosis
Primary: Gout, hypertension
Secondary: Diabetes mellitus, constipation, knee replacement, dermatitis

Medication record
 
Date
RX No
Name and Strength
Route
Quantity
Sig
1.
6/8
11331
Indocin® 25 mg
PO
30
i tid
2.
6/8
11332
Aristocort cream
Topical
30 g
i tid
3.
6/23
12114
Amaryl® 1 mg
PO
30
i qd
4.
6/28
13103
Dyazide
PO
30
i bid
5.
6/28
13104
Micronase 5 mg
PO
60
ii qam
6.
7/20
14231
Micronase 5 mg
PO
30
i qpm
7.
9/7
15301
Coumadin® 4 mg
PO
30
i qd
8.
10/11
16241
Milk of magnesia
PO
480
30 cc prn
9.
11/5
17332
Dulcolax® supp 10 mg
PR
30
i qd prn
10.
11/5
17333
Vicodin® 5/500
PO
30
i q4h prn
11.
11/5
17334
Tylenol® 325 mg
PO
30
i q4h prn
 
Use the patient profile above to answer the following questions.

1.
Based on this patient's profile, which diabetes type is he being treated for?
I. Noninsulin-dependent diabetes mellitus
II. Diabetes mellitus type 1
III. Diabetes mellitus type 2
A.
I only
B.
II only
C.
III only
D.
I and III
E.
I and III


2.
Pharmacologic classifications for Amaryl® include
I. Sulfonylurea agent
II. Hypoglycemic agent
III. Thiazolidinedione derivative agent
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


3.
Dyazide in this patient is being used to treat his
I. Gout
II. Hypertension
III. Dermatitis
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I, II, and III


4.
Parameters that should be monitored for patients taking Amaryl® include
I. Glucose and ketones in urine
II. Fasting blood glucose
III. Liver enzymes every two months for the first year of therapy
A.
I
B.
II
C.
III
D.
I and II
E.
II and III


5.
Reasons for this patient to be on Coumadin® include
I. Prophylaxis of systemic embolism from gout
II. Improve the management of his diabetes mellitus
III. Prophylaxis of systemic embolism after knee replacement
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


6.
Which choices best explain the addition of Micronase to this patient's profile on 7/20
I. Improve INR readings for Coumadin®
II. Improve fasting blood glucose levels
III. Improve serum uric acid levels
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


7.
Clinical presentation of patients experiencing diabetic ketoacidosis include
I. Changes in mental status
II. Nausea and vomiting
III. Fruity odor to the breath
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I, II, and III


8.
The dose for Micronase should be adjusted in patients with renal impairment. What lab values are taken into account for dosage adjustments in renal impairment?
I. Uric acid levels in the serum
II. Amounts of ketones in the urine
III. Creatinine clearance
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I, II, and III


9.
Based on his medical profile you could conclude that this patient is taking Indocin®, Tylenol®, and Vicodin® to treat his
I. Dermatitis
II. Knee replacement
III. Gout
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I, II, and III


10.
Based on his medical profile you could conclude that this patient is using Aristocort cream to treat his
I. Gout
II. Dermatitis
III. Knee replacement
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I, II, and III


11.
Which of the drugs listed in Mr. Doe's medication profile could interact with Coumadin® to increase his INR
I. Indocin®
II. Dyazide
III. Micronase
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I and III


12.
Drugs listed in Mr. Doe's profile that could decrease the effects of Micronase include
I. Coumadin®
II. Dyazide
III. Indocin®
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I and III


STOP This is the end of the test. When you have completed all the questions and reviewed your answers, press the button below to grade the test.